MHC-independent tumor-associated antigens

US10987413B2 · kind B2 · utility

Assignee

• BIONTECH RNA PHARMACEUTICALS GMBH · DE

Inventors

• Dirk Schadendorf · Essen, DE
• Annette Paschen · Essen, DE
• Silke Lübcke · Munich, DE
• Martina Fatho · Wörrstadt, DE
• Daniela Eberts · Gau-Algesheim, DE
• Hakim Echchannaoui · Mainz, DE
• Volker Lennerz · Ober-Olm, DE
• Catherine Woelfel · Mainz, DE
• Thomas Woelfel · Mainz, DE

Key dates

• Filing date: Nov 30, 2017
• Grant date: Apr 27, 2021
• Expiry date: Oct 3, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Y503/03012
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel tumor-associated antigens, which elicit independently from a presentation via MHC a CD8-positive T-cell response. GM-CSF-Receptor alpha chain (CSF2RA) and Tyrosinase-related protein 2 (TRP-2) were found to be targets of CD8-positive T-cell clones which could detect the proteins on the surface of HLA I negative melanoma cells. Thus, the invention provides proteins, protein fragments and polypeptides of the novel antigens for use in medicine, for example for the treatment, diagnosis and prevention of a tumor disease. Furthermore provided are nucleic acids expressing the antigens of the invention, binding agents specific for the antigens of the invention, such as T-cell receptor chains and isolated T cells which are reactive against the antigens of the invention or which express the T-cell receptors of the invention. The invention further pertains to pharmaceutical compositions, especially vaccine compositions, comprising the antigens, nucleic acids, binding agents or T cells in accordance with the invention, and methods for the generation of T cells, which are specifically reactive to the antigens of the invention in an MHC-independent manner.